

# Mi Young Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135141/publications.pdf>

Version: 2024-02-01

9  
papers

65  
citations

1684188  
5  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of radiation dose on complications among women with breast cancer who underwent breast reconstruction and post-mastectomy radiotherapy: A multi-institutional validation study. <i>Breast</i> , 2021, 56, 7-13.	2.2	14
2	Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 208-216.	1.5	13
3	5-year oncological outcomes of targeted axillary sampling in pT1-2N1 breast cancer. <i>Asian Journal of Surgery</i> , 2019, 42, 681-687.	0.4	10
4	Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 449-455.	1.4	8
5	Local and regional recurrence following mastectomy in breast cancer patients with 1-3 positive nodes: implications for postmastectomy radiotherapy volume. <i>Radiation Oncology Journal</i> , 2018, 36, 285-294.	1.5	8
6	Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	4
7	Mapping patterns of para-aortic lymph node recurrence in cervical cancer: a retrospective cohort analysis. <i>Radiation Oncology</i> , 2021, 16, 128.	2.7	3
8	Postmastectomy Radiation Therapy for Node-Negative Breast Cancer of 5 cm or Larger Tumors: A Multicenter Retrospective Analysis (KROG 20-03). <i>Cancer Research and Treatment</i> , 2022, 54, 497-504.	3.0	3
9	Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701). <i>Cancers</i> , 2020, 12, 3261.	3.7	2